The FDA ( Food and Drug Administration ) has granted accelerated approval to Opdivo ( Nivolumab ), a new treatment for patients with unresectable ( cannot be removed by surgery ) or metastatic ( advanced ) melanoma who no longer respond to other drugs.
Melanoma is the fifth most common type of cancer in the United States. It forms in the body’s melanocyte cells, which develop the skin’s pigment.
The National Cancer Institute ( NCI ) estimates that 76,100 Americans will be diagnosed with melanoma and 9,710 will die from the disease this year.
Opdivo works by inhibiting the PD-1 protein on cells, which blocks the body’s immune system from attacking melanoma tumors. Opdivo is intended for patients who have been previously treated with Ipilimumab ( Yervoy ) and, for melanoma patients whose tumors express a gene mutation called BRAF V600, for use after treatment with Ipilimumab and a BRAF inhibitor.
Opdivo is the seventh new melanoma drug approved by the FDA since 2011. Other FDA-approved treatments for melanoma include Ipilimumab ( 2011 ), Peginterferon alfa-2b ( 2011 ), Vemurafenib ( 2011 ), Dabrafenib ( 2013 ), Trametinib ( 2013 ) and Pembrolizumab ( 2014 ).
Opdivo is being approved more than three months ahead of the prescription drug user fee goal date of March 30, 2015, the date when the agency was scheduled to complete its review of the application.
The FDA granted Opvido breakthrough therapy designation, priority review and orphan product designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies; the drug had the potential, at the time of the application was submitted, to be a significant improvement in safety or effectiveness in the treatment of a serious condition; and the drug is intended to treat a rare disease, respectively.
Opvido is being approved under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts additional clinical trials to confirm the drug’s benefit.
Opdivo’s efficacy was demonstrated in 120 clinical trial participants with unresectable or metastatic melanoma. Results showed that 32% of participants receiving Opdivo had their tumors shrink ( objective response rate, ORR ). This effect lasted for more than six months in approximately one-third of the participants who experienced tumor shrinkage.
Opdivo’s safety was evaluated in the overall trial population of 268 participants treated with Opdivo and 102 participants treated with chemotherapy.
The most common side effects of the drug were rash, itching, cough, upper respiratory tract infections, and fluid retention ( edema ).
The most serious side effects are severe immune-mediated side effects involving healthy organs, including the lung, colon, liver, kidneys and hormone-producing glands. ( Xagena )
Source: FDA, 2014